Dual therapy with lopinavir/ritonavir plus lamivudine could be a viable alternative for antiretroviral-therapy-naive adults with HIV-1 infection regardless of HIV viral load or subgenotype in resource-limited settings: A randomised, open-label and non-inferiority study from China

Indian J Med Microbiol. 2018 Oct-Dec;36(4):513-516. doi: 10.4103/ijmm.IJMM_18_172.

Abstract

Backgrounds: This randomised controlled, open-label, non-inferiority trial was conducted in antiretroviral-naïve HIV-1-infected patients to assess the efficacy and safety of 48-week dual therapy of LPV/r plus 3TC (DT group) compared with Chinese first-line triple-therapy regimen (TT group).

Methods: 198 were randomised to DT (n = 100) or TT (n = 98).

Results: Ninety-two DT patients (92%) and 88 TT patients (89.8%) achieved HIV-1 RNA <50 copies/ml at week 48 (P = 0.629). Moreover, the safety profile was similar between two groups, and no secondary HIV resistance was observed.

Conclusion: The results suggest that dual therapy of LPV/r plus 3TC is non-inferior to the first-line triple-therapy regimen in China.

Keywords: Antiretroviral therapy; efavirenz; lopinavir/ritonavir; randomised controlled study; simplified regimen.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-HIV Agents / administration & dosage*
  • Anti-HIV Agents / adverse effects
  • Antiretroviral Therapy, Highly Active / adverse effects
  • Antiretroviral Therapy, Highly Active / methods*
  • China
  • Drug-Related Side Effects and Adverse Reactions / epidemiology
  • Drug-Related Side Effects and Adverse Reactions / pathology
  • Female
  • HIV Infections / drug therapy*
  • HIV-1 / isolation & purification*
  • Humans
  • Lamivudine / administration & dosage*
  • Lamivudine / adverse effects
  • Lopinavir / administration & dosage*
  • Lopinavir / adverse effects
  • Male
  • Middle Aged
  • Ritonavir / administration & dosage*
  • Ritonavir / adverse effects
  • Treatment Outcome
  • Viral Load
  • Young Adult

Substances

  • Anti-HIV Agents
  • Lopinavir
  • Lamivudine
  • Ritonavir